RO7296682
- Generic Name
- RO7296682
- Drug Type
- Biotech
- Unique Ingredient Identifier
- HV8TQI2IKP
Overview
RO7296682 is a monoclonal antibody against CD25 (IL-2R alpha) expressed on tumour-infiltrating regulatory T (T) cells. RO7296682 is under investigation in clinical trial NCT04642365 (A Study to Evaluate the Safety and Tolerability of RO7296682 in Combination With Atezolizumab in Participants With Advanced Solid Tumors.).
Background
RO7296682 is a monoclonal antibody against CD25 (IL-2R alpha) expressed on tumour-infiltrating regulatory T (T) cells. RO7296682 is under investigation in clinical trial NCT04642365 (A Study to Evaluate the Safety and Tolerability of RO7296682 in Combination With Atezolizumab in Participants With Advanced Solid Tumors.).
Indication
No indication information available.
Associated Conditions
No associated conditions information available.
Clinical Trials
FDA Approved Products
Singapore Approved Products
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.